420 with CNW – Tilray, Inc. (NASDAQ: TLRY) Announces Positive Research Results for Cancer Sufferers

Medical cannabis is probably one of the most controversial topics at the moment. Critics of the medical marijuana movement have claimed that there is hardly any evidence of therapeutic benefit and that the hype has far outpaced the science. On the other hand, cannabis reform activists have argued that due to its diverse medicinal properties, medical cannabis can be a great alternative to pharmaceuticals.

Quite recently, Tilray (NASDAQ: TLRY) announced that Australian researchers have found that medical cannabis has shown promise as a treatment for nausea and vomiting for cancer patients undergoing chemotherapy in a clinical trial. The trial’s preliminary findings, which showed a significant improvement in the control of chemotherapy-induced nausea and vomiting, were published in the Annals of Oncology. The pilot phase of the study consisted of 81 patients who had experienced nausea and vomiting during chemotherapy and it ran for two and a half years.

A quarter of the participants taking medical cannabis experienced no vomiting or nausea compared to 14 percent of people who took a placebo. “The side-effects associated with chemotherapy are some of the primary causes of treatment discontinuation,” says Philippe Lucas, Vice President of Global Research and Access at Tilray, “so improving the control of nausea and vomiting can not only improve the quality of life of patients, but by allowing those affected by cancer to complete their treatment it can also potentially save lives.”

At the moment, the most prescribed medicine for chemo-induced nausea is the synthetic drug Marinol, owned by biotech company AbbVie. However, plenty of patients have been unable to continue with it due to side effects such as mood changes, confusion, trouble concentrating, dizziness, and anxiety. “Nausea and vomiting are among the most distressing and feared consequences of chemotherapy,” says Peter Grimson, leader of the study, medical oncologist at Chris O’Brien Lifehouse and Associate Professor at the University of Sidney.

Although side effects such as sedation, drowsiness, and dizziness were present in moderate to severe levels in about one-third of the people using medical cannabis, researchers considered them manageable. “These encouraging results indicate medical cannabis can help improve quality of life for chemotherapy patients,” Grimson says.

“The trial will now move to a larger phase to determine with much more certainty how effective medicinal cannabis is and whether it should be considered for use in routine cancer care. The next phase of the trial is ongoing and will recruit an extra 170 people.” Grimson added.

Experts say this research goes a long way towards confirming what pot companies like Pac Roots Cannabis Corp. (CSE: PACR) have always said about the myriad of benefits of marijuana.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Archives

Select A Month
  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • September 2016
  • August 2016
  • July 2016
  • Official NewsWire Relationships

    Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

    CannabisNewsWire Currently Accepts

    Bitcoin

    Bitcoin

    Bitcoin Cash

    Bitcoin Cash

    Doge Coin

    Dogecoin

    Ethereum

    Ethereum

    Litecoin

    Litecoin

    USD Coin

    USD Coin

    Contact us: 512.354.7000